Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman & CEO | 1.27M | -- | 1961 |
| Mr. Geoffrey Robin Race F.C.M.A., M.B.A. | President | 913.3k | -- | 1961 |
| Mr. Frederick W. Ahlholm CPA | Senior VP, CFO & Secretary | 726.02k | -- | 1966 |
| Mr. Joseph Reilly | Senior VP & COO | 461k | -- | 1975 |
| Mr. William B. Boni | Vice President of Investor Relations & Corporate Communications | -- | -- | 1952 |
| Prof. Michael Davidson M.D. | Chief Medical Officer | 657.47k | -- | 1950 |
Minerva Neurosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Corporate Governance
Upcoming Events
February 20, 2025 at 1:30 PM UTC - February 24, 2025 at 1:30 PM UTC
Minerva Neurosciences, Inc. Earnings Date